General

Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents. Cook G. Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.175. [Epub ahead of print]. IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature. Mitra S et al. Indian J Hematol Blood Transfus. 2015 Dec;31(4):472-9. doi: 10.1007/s12288-014-0454-5.…

Details

Complications of myeloma and its treatments

Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy. Gu ZH et al. Int J Clin Exp Med. 2015 Jun 15;8(6):10105-10108. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Vincent L et al. Blood Cancer J. 2015 Aug 21;5:e341. doi: 10.1038/bcj.2015.48. Hematopoietic cell transplantation in patients with medication-related osteonecrosis of the jaws. Mawardi…

Details

Current treatments

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.60.2466. [Epub ahead of print]. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myelomapatients aged 65 years or older: a retrospective single Institutional analysis. Minoia C et al. Bone Marrow Transplant. 2015 Aug…

Details

NICE issues new draft guidelines for end of life care

The National Institute for Health and Care Excellence (NICE) has issued draft guidelines for consultation to improve the care of adults during the last few days of life. The guidelines are meant to replace the Liverpool Care Pathway which were phased out in 2014. Key recommendations highlight the importance of communication and shared decision-making involving…

Details

Publication of revised International Staging System for myeloma

The International Myeloma Working Group (IMWG) has revised the International Staging System (ISS) to enable better stratification of newly diagnosed myeloma patients. It now includes the detection of chromosomal abnormalities (CA) by interphase fluorescent in situ hybridisation (iFISH) and the measurement of serum lactate dehydrogenase (LDH) which, when combined with the previous ISS, provides powerful…

Details

Diagnostic tests and prognostic indicators

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ayuk F et al. Ann Hematol. 2015 Jul 24. [Epub ahead of print]. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Oral A et al. Clin Nucl Med. 2015 Jul 22. [Epub ahead of print]. Tumor associated macrophages (TAMs) and extraczellular…

Details

Related conditions

Neoplastic and Non-Neoplastic Complications of Solid Organ Transplantation in Patients with Preexisting Monoclonal Gammopathy of Undetermined Significance (MGUS). Goebel TE et al. Clin Transplant. 2015 Jul 21. doi: 10.1111/ctr.12595. [Epub ahead of print]. Kidney involvement in Crow-Fukase syndrome. Zouaghi K et al. Saudi J Kidney Dis Transpl. 2015 Jul-Aug;26(4):751-6. doi: 10.4103/1319-2442.160201. Bortezomib produces high hematological response rates with prolonged renal survival…

Details

Emerging treatments

T-cell receptor therapy shows promise in multiple myeloma. Bagcchi S. Lancet Oncol. 2015 Jul 23. pii: S1470-2045(15)00191-6. doi: 10.1016/S1470-2045(15)00191-6. [Epub ahead of print]. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Rapoport AP et al. Nat Med. 2015 Jul 20. doi: 10.1038/nm.3910. [Epub ahead of print]. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple…

Details

Biology and genetics

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Mitchell JS et al. Sci Rep. 2015 Jul 24;5:12473. doi: 10.1038/srep12473. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Lazareth A et al. Haematologica. 2015 Jul 23. pii: haematol.2015.127001. [Epub ahead of print]. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of…

Details